Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5148 for Prevention of Recurrence of Clostridioides Difficile Infection
NCT07285213Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of azd5148 in Clostridioides difficile infection (CDI), sponsored by AstraZeneca. Started Dec 2025; status: recruiting.
02
Drugs
azd5148
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07285213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285213.